Asti Swari Paramanindita

Ms. Asti Swari Paramanindita

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2020 in Drug Development and Industrial Pharmacy
Verified
Journal Article
Closed access
APAsti Swari Paramanindita
Asti Swari Paramanindita
YHYahdiana Harahap
Yahdiana Harahap
BPBudi Prasaja
Budi Prasaja
TWTri Rahayu Wijayanti
Tri Rahayu Wijayanti
WLWindy Lusthom
Windy Lusthom
YTYunia Trisari
Yunia Trisari
Telmisartan is highly variable drug indicated for treatment of hypertension. This study aimed to compare the bioavailability of two 80 mg telmisartan tablets in healthy Indonesian subjects. A randomized, open-label, single-dose, three-sequence, three-way, reference-formulation-replicated crossover study was conducted under fasting period with two-week washout period. In this study, thirty-one Indonesian subjects were enrolled and twenty-eight subjects were completed the study. Serial blood samples were collected up to 72 hours following drug administration. Plasma concentrations of telmisartan were determined using high performance liquid chromatography method with fluorescence detector. The pharmacokinetic parameters of AUC0-t, AUC0-∞, and Cmax were assessed for bioequivalence. Bioequivalence acceptance was based on predefined criteria of 90% confidence interval of 80.00-125.00% for AUC parameters and reference-scaled-average bioequivalence of 71.73-139.42% for Cmax. The 90% confidence interval for AUC0-t, AUC0-∞, and Cmax were 96.11%-107.25%, 93.06%-104.36%, and 94.23%-127.01%, respectively. These results indicated that the two formulations of telmisartan were bioequivalent.